{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:41:20Z","timestamp":1792640480370,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-15-00040"],"award-info":[{"award-number":["AID-OAA-A-15-00040"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011071","name":"FHI 360","doi-asserted-by":"publisher","award":["AID-674-A-14-00009"],"award-info":[{"award-number":["AID-674-A-14-00009"]}],"id":[{"id":"10.13039\/100011071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004695","name":"University of KwaZulu-Natal","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004695","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New pre-exposure prophylaxis (PrEP) strategies tailored to the needs and expectations of individuals at risk of HIV acquisition are needed. In the CAPRISA 082 prospective cohort study in KwaZulu-Natal, South Africa, sexually active women aged 18 to 30 reported, through interviewer-administered questionnaires, on their prior contraceptive experience and interest in both approved and potential future PrEP dosage forms (oral PrEP, long-acting injectable PrEP, and PrEP implants) between March 2016 and February 2018. Univariable and multivariable Poisson regression models with robust standard errors were used to detect associations between women\u2019s prior and current contraceptive use and interest in PrEP options. Of 425 women enrolled, 381 (89.6%) had used at least one modern female contraceptive method previously, with injectable depot medroxyprogesterone acetate (DMPA) being used by 79.8% (n\u2009=\u2009339). Women were more likely to show interest in a future PrEP implant if they were currently using (aRR 2.1, CI 1.43\u20133.07, p\u2009=\u20090.0001) or had ever used (aRR 1.65, CI 1.14\u20132.40, p\u2009=\u20090.0087) a contraceptive implant, and were more likely to choose an implant as their first choice method than the implant-na\u00efve (current users aRR 3.2, CI 1.79\u20135.73, p\u2009&lt;\u20090.0001; \u201cever\u201d users aRR 2.12, CI 1.16\u20133.86, p\u2009=\u20090.0142). Women were more interested in injectable PrEP if they had used injectable contraceptives (current users aRR 1.24, CI 1.06\u20131.46, p\u2009=\u20090.0088; \u201cever\u201d users aRR 1.72, CI 1.20\u20132.48, p\u2009=\u20090.0033); and were more interested in oral PrEP if they had ever used oral contraceptives (aRR 1.3, CI 1.06\u20131.59, p\u2009=\u20090.0114). This apparent relationship between women\u2019s contraceptive experience and their interest in novel forms of PrEP in an equivalent dosage form may play a future role in strengthening HIV prevention efforts in women at high risk of HIV acquisition.<\/jats:p>","DOI":"10.1007\/s10461-023-04072-6","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:44:37Z","timestamp":1684863877000},"page":"3596-3602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-7745","authenticated-orcid":false,"given":"Claudia J.","family":"Jansen van Vuuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishana","family":"Harkoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"4072_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics\u2014Fact sheet 2022. 2022. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 7 Feb 2023."},{"key":"4072_CR2","volume-title":"Global AIDS strategy 2021\u20132026","author":"UNAIDS","year":"2021","unstructured":"UNAIDS. Global AIDS strategy 2021\u20132026. Geneva: World Health Organization; 2021."},{"issue":"4","key":"4072_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bpobgyn.2012.01.005","volume":"26","author":"S Sibeko","year":"2012","unstructured":"Sibeko S, Cohen GM, Moodley J. Contraception and pregnancy in microbicide trials. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):473\u201386.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"6394","key":"4072_CR4","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1126\/science.aau2663","volume":"360","author":"Q Abdool Karim","year":"2018","unstructured":"Abdool Karim Q, Abdool Karim SS. HIV-No time for complacency. Science. 2018;360(6394):1153.","journal-title":"Science"},{"key":"4072_CR5","volume-title":"Primary health care systems (PRIMASYS): case study from South Africa","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Primary health care systems (PRIMASYS): case study from South Africa. Geneva: World Health Organization; 2017."},{"issue":"1","key":"4072_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.4102\/sajhivmed.v21i1.1152","volume":"21","author":"L Bekker","year":"2020","unstructured":"Bekker L, Brown B, Joseph-Davey D, et al. Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020. S Afr J HIV Med. 2020;21(1):1152.","journal-title":"S Afr J HIV Med"},{"issue":"1","key":"4072_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4102\/sajhivmed.v17i1.455","volume":"17","author":"L Bekker","year":"2016","unstructured":"Bekker L, Rebe K, Venter F, et al. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. S Afr J HIV Med. 2016;17(1):455.","journal-title":"S Afr J HIV Med"},{"issue":"6","key":"4072_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003670","volume":"18","author":"C Celum","year":"2021","unstructured":"Celum C, Hosek S, Tsholwana M, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6): e1003670.","journal-title":"PLoS Med"},{"issue":"12","key":"4072_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","volume":"319","author":"J Riddell","year":"2018","unstructured":"Riddell J, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018;319(12):1261\u20138.","journal-title":"JAMA"},{"issue":"7","key":"4072_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25957","volume":"25","author":"LE Mansoor","year":"2022","unstructured":"Mansoor LE, Lewis L, Naicker CL, et al. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa. J Int AIDS Soc. 2022;25(7):e25957.","journal-title":"J Int AIDS Soc."},{"key":"4072_CR11","unstructured":"International Partnership for Microbicides. South Africa approves dapivirine vaginal ring for use by women. 2022. https:\/\/www.ipmglobal.org\/content\/south-africa-approves-dapivirine-vaginal-ring-use-women. Accessed 17 Apr 2022."},{"key":"4072_CR12","unstructured":"South African Health Products Regulatory Authority. SAHPRA Registers New Long-Acting HIV Pre-Exposure Prophylaxis. 2022. https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2022\/12\/MEDIA-RELEASE-New-HIV-HIV-pre-exposure-prophylaxis-2-Dec-2022.pdf. Accessed 6 Feb 2023."},{"issue":"22","key":"4072_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med"},{"issue":"22","key":"4072_CR14","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"4072_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s10461-021-03512-5","volume":"26","author":"J Etima","year":"2022","unstructured":"Etima J, Katz AWK, Duby Z, et al. Does the ring work? Perceptions and understanding of the efficacy of a dapivirine vaginal ring for HIV prevention amongst women in a placebo-controlled trial. AIDS Behav. 2022;26(5):1597\u2013606.","journal-title":"AIDS Behav"},{"issue":"8","key":"4072_CR16","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1007\/s10461-021-03205-z","volume":"25","author":"AJ Mayo","year":"2021","unstructured":"Mayo AJ, Browne EN, Montgomery ET, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention and association with adherence in a phase III trial. AIDS Behav. 2021;25(8):2430\u201340.","journal-title":"AIDS Behav"},{"issue":"10337","key":"4072_CR17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"4","key":"4072_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.7326\/M21-1548","volume":"175","author":"AM Neilan","year":"2022","unstructured":"Neilan AM, Landovitz RJ, Le MH, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175(4):479\u201389.","journal-title":"Ann Intern Med"},{"key":"4072_CR19","unstructured":"Owings L. South Africa must urgently start planning roll-out of HIV-prevention injection, say experts. 2022. https:\/\/www.dailymaverick.co.za\/article\/2022-02-22-south-africa-must-urgently-start-planning-roll-out-of-hiv-prevention-injection-say-experts\/. Accessed 17 Apr 2022."},{"issue":"12","key":"4072_CR20","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2352-3018(22)00251-X","volume":"9","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Johnson LF, Nichols BE, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022;9(12):e857\u201367.","journal-title":"Lancet HIV"},{"key":"4072_CR21","unstructured":"Centre for the AIDS Programme of Research in South Africa (CAPRISA). CAPRISA Studies. 2023; Available at: https:\/\/www.caprisa.org\/Pages\/CAPRISAStudies.\u00a0Accessed 10 Feb 2023."},{"issue":"2","key":"4072_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/QAI.0000000000000413","volume":"68","author":"R Callahan","year":"2015","unstructured":"Callahan R, Nanda K, Kapiga S, et al. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. J Acquir Immune Defic Syndr. 2015;68(2):196\u2013203.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"4072_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019490","volume":"99","author":"M Hlongwa","year":"2020","unstructured":"Hlongwa M, Mashamba-Thompson T, Makhunga S, Hlongwana K. Evidence on factors influencing contraceptive use and sexual behavior among women in South Africa: a scoping review. Medicine (Baltimore). 2020;99(12): e19490.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4072_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089118","volume":"9","author":"A van der Straten","year":"2014","unstructured":"van der Straten A, Stadler J, Montgomery E, et al. Women\u2019s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2): e89118.","journal-title":"PLoS ONE"},{"issue":"5","key":"4072_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jadohealth.2021.04.031","volume":"69","author":"NF Fields","year":"2021","unstructured":"Fields NF, Wood S, Amutah C, Timko CA, Petsis D, Akers AY. Identifying opportunities to discuss pre-exposure prophylaxis during contraceptive coaching discussions with urban adolescent women. J Adolesc Health. 2021;69(5):824\u201330.","journal-title":"J Adolesc Health"},{"issue":"1","key":"4072_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12978-020-00970-3","volume":"17","author":"K Jonas","year":"2020","unstructured":"Jonas K, Duby Z, Maruping K, et al. Perceptions of contraception services among recipients of a combination HIV-prevention interventions for adolescent girls and young women in South Africa: a qualitative study. Reprod Health. 2020;17(1):122\u20133.","journal-title":"Reprod Health"},{"issue":"5","key":"4072_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"4072_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QAI.0000000000003021","volume":"91","author":"V Kamire","year":"2022","unstructured":"Kamire V, Magut F, Khagayi S, et al. HIV risk factors and risk perception among adolescent girls and young women: results From a population-based survey in Western Kenya, 2018. J Acquir Immune Defic Syndr. 2022;91(1):17\u201325.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"4072_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198680","volume":"13","author":"EA Warren","year":"2018","unstructured":"Warren EA, Paterson P, Schulz WS, et al. Risk perception and the influence on uptake and use of biomedical prevention interventions for HIV in sub-Saharan Africa: a systematic literature review. PLoS ONE. 2018;13(6): e0198680.","journal-title":"PLoS ONE"},{"issue":"7","key":"4072_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2352-3018(16)30063-7","volume":"3","author":"JR Hargreaves","year":"2016","unstructured":"Hargreaves JR, Delany-Moretlwe S, Hallett TB, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. Lancet HIV. 2016;3(7):318.","journal-title":"Lancet HIV"},{"issue":"5","key":"4072_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/hpm.3252","volume":"36","author":"J Lane","year":"2021","unstructured":"Lane J, Brezak A, Patel P, Verani AR, Benech I, Katz A. Policy considerations for scaling up access to HIV pre-exposure prophylaxis for adolescent girls and young women: examples from Kenya, South Africa, and Uganda. Int J Health Plan Manage. 2021;36(5):1789\u2013808.","journal-title":"Int J Health Plan Manage"},{"issue":"1","key":"4072_CR32","doi-asserted-by":"publisher","first-page":"20123","DOI":"10.7448\/IAS.18.1.20123","volume":"18","author":"JM Hagey","year":"2015","unstructured":"Hagey JM, Akama E, Ayieko J, Bukusi EA, Cohen CR, Patel RC. Barriers and facilitators adolescent females living with HIV face in accessing contraceptive services: a qualitative assessment of providers\u2019 perceptions in western Kenya. J Int AIDS Soc. 2015;18(1):20123.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"4072_CR33","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.socscimed.2009.02.041","volume":"68","author":"N Angotti","year":"2009","unstructured":"Angotti N, Bula A, Gaydosh L, Kimchi EZ, Thornton RL, Yeatman SE. Increasing the acceptability of HIV counseling and testing with three C\u2019s: convenience, confidentiality and credibility. Soc Sci Med. 2009;68(12):2263\u201370.","journal-title":"Soc Sci Med"},{"issue":"8","key":"4072_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/heapol\/czw035","volume":"31","author":"A Brunie","year":"2016","unstructured":"Brunie A, Wamala-Mucheri P, Akol A, Mercer S, Chen M. Expanding HIV testing and counselling into communities: feasibility, acceptability, and effects of an integrated family planning\/HTC service delivery model by Village Health Teams in Uganda. Health Policy Plan. 2016;31(8):1050\u20137.","journal-title":"Health Policy Plan"},{"issue":"7","key":"4072_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25968","volume":"25","author":"A Medina-Marino","year":"2022","unstructured":"Medina-Marino A, Bezuidenhout D, Ngwepe P, et al. Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa. J Int AIDS Soc. 2022;25(7): e25968.","journal-title":"J Int AIDS Soc"},{"key":"4072_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2021.704841","volume":"3","author":"B Young Holt","year":"2021","unstructured":"Young Holt B, Turpin JA, Romano J. Multipurpose prevention technologies: opportunities and challenges to ensure advancement of the most promising MPTs. Front Reprod Health. 2021;3: 704841.","journal-title":"Front Reprod Health"},{"key":"4072_CR37","unstructured":"The Initiative for Multipurpose Prevention Technologies. MPT Product Development Database. 2022. https:\/\/mpts101.org\/. Accessed 6 Feb 2023."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04072-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-023-04072-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04072-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:10:52Z","timestamp":1697800252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-023-04072-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["4072"],"URL":"https:\/\/doi.org\/10.1007\/s10461-023-04072-6","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"26 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the University of KwaZulu\u2010Natal's Biomedical Research Ethics Committee (BE458\/15).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}